Targeting the oncogene eIF4E in cancer: From the bench to clinical trials

Borden, Katherine L. B.
December 2011
Clinical & Investigative Medicine;Dec2011, Vol. 34 Issue 6, pE315
Academic Journal
Identifying and targeting specific oncogenes, with the hope that the resultant therapies may eventually prove to exert positive clinical effects, is a major effort in the area of cancer therapeutics. The eukaryotic translation initiation factor, eIF4E, is overexpressed in many cancers, including acute myeloid leukemia. The role of eIF4E in oncogenic transformation and the development of a means to directly target its activity with ribavirin are discussed here. Results from early stage clinical trials and factors contributing to the development of clinical resistance to ribavirin are also described.


Related Articles

  • Characterization of microRNA-29 family expression and investigation of their mechanistic roles in gastric cancer. Gong, Jianan; Li, Jianxiong; Wang, Yi; Liu, Changzheng; Jia, Hongyan; Jiang, Chongliang; Wang, Yuxuan; Luo, Min; Zhao, Hongmei; Dong, Lei; Song, Wei; Wang, Fang; Wang, Weibin; Zhang, Junwu; Yu, Jia // Carcinogenesis;Feb2014, Vol. 35 Issue 2, p497 

    MicroRNA-29 family in gastric cancer.Increasing evidence shows that abnormal microRNAs (miRNAs) expression is involved in tumorigenesis. They might be the novel biomarkers or therapeutic targets in disease treatment. miR-29 family was previously reported to act as tumor suppressors or oncogenes...

  • Neighborhood Rough Set Reduction-Based Gene Selection and Prioritization for Gene Expression Profile Analysis and Molecular Cancer Classification. Mei-Ling Hou; Shu-Lin Wang; Xue-Ling Li; Ying-Ke Lei // Journal of Biomedicine & Biotechnology;2010, p1 

    Selection of reliable cancer biomarkers is crucial for gene expression profile-based precise diagnosis of cancer type and successful treatment. However, current studies are confronted with overfitting and dimensionality curse in tumor classification and false positives in the identification of...

  • The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Hsu, Tiffany Y.-T.; Simon, Lukas M.; Neill, Nicholas J.; Marcotte, Richard; Sayad, Azin; Bland, Christopher S.; Echeverria, Gloria V.; Sun, Tingting; Kurley, Sarah J.; Tyagi, Siddhartha; Karlin, Kristen L.; Dominguez-Vida├▒a, Rocio; Hartman, Jessica D.; Renwick, Alexander; Scorsone, Kathleen; Bernardi, Ronald J.; Skinner, Samuel O.; Jain, Antrix; Orellana, Mayra; Lagisetti, Chandraiah // Nature;9/17/2015, Vol. 525 Issue 7569, p384 

    MYC (also known as c-MYC) overexpression or hyperactivation is one of the most common drivers of human cancer. Despite intensive study, the MYC oncogene remains recalcitrant to therapeutic inhibition. MYC is a transcription factor, and many of its pro-tumorigenic functions have been attributed...

  • Pace of Gene Therapy Picking Up. Marwick, Charles // JAMA: Journal of the American Medical Association;11/20/91, Vol. 266 Issue 19, p2668 

    Reports that an advisory committee of the National Institutes of Health (NIH), Bethesda, Maryland, has given permission to investigators from the National Cancer Institute of NIH to extend their use of gene therapy in cancer. Concept in the cancer study; Objective of the study; Details on...

  • New insights into oncogenic stress. Haigis, Kevin M.; Sweet-Cordero, Alejandro // Nature Genetics;Mar2011, Vol. 43 Issue 3, p177 

    Expression of oncogenes in otherwise normal cells often leads to the activation of anti-oncogenic pathways through a poorly understood process described as 'oncogenic stress'. A new study implicates the Jnk pathway signaling in the activation of p53 in response to both K-Ras and Neu oncogene...

  • tumour biology and pathology.  // Annals of Oncology;2016 Supplement, Vol. 27, pvi545 

    No abstract available.

  • Introduction: RNA and The Treatment of Human Cancer. Bruserud, ├łystein // Current Pharmaceutical Biotechnology;Dec2007, Vol. 8 Issue 6, p318 

    Epigenetic events are important in carcinogenesis and for the susceptibility of malignant cells to chemotherapy, and this knowledge has identified a new generation of oncogenes and thereby also a new class of possible therapeutic targets for anticancer treatment. RNA reflects gene expression and...

  • dbCerEx: A Web-Based Database for the Analysis of Cervical Cancer Transcriptomes. Zhou, Limin; Zheng, Wei; Luo, Majing; Feng, Jing; Jin, Zhichun; Wang, Yan; Zhang, Dunlan; Tang, Qiongxiu; He, Yan // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    Background: Cervical cancers are ranked the second-most hazardous ailments among women worldwide. In the past two decades, microarray technologies have been applied to study genes involved in malignancy progress. However, in most of the published microarray studies, only a few genes were...

  • Developmental Milieu Influences a Gene's Role in Tumor Formation.  // PLoS Biology;Nov2004, Vol. 2 Issue 11, p1688 

    The article reports that inherited defective gene or genetic damage play a role in transforming a healthy cell into a cancer cell. Oncogenes and tumor suppressor genes are normally involved in cell growth, development, and cell differentiation. Single mutations in these genes rarely cause cancer...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics